Teva and Alvotech have announced receipt of the US FDA approval to Selarsdi injection for use as an interchangeable with Stelara.

Bevacizumab is typically obtained through such compounding pharmacies; whereas ranibizumab and aflibercept are both packaged as single-use vials of medication for each one-time injection.

Teva Pharmaceuticals and Alvotech have announced that the US Food and Drug Administration (FDA) has approved the Selarsdi (ustekinumab-aekn) injection as interchangeable with reference biologic ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

MiscellaneousFormycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz) 19.05.2025 / 15:00 CET/CESTThe issuer is solely responsible for the content ...

[1,2] Pyzchiva® is also available as a 130mg concentrate in a vial for solution for infusion, a 90 mg and a 45 mg concentrate solution for injection in a pre-filled syringe. *Pyzchiva® is a ...

Approved presentations of SELARSDI are 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection, 45 mg/0.5 mL in a single-dose vial for subcutaneous injection and ...

As Avastin needs to be removed from its original vials and introduced into single-use syringes suitable for injection into ... Bayer’s Eylea (aflibercept). Novartis and Roche launched a ...